Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Convertible Debt (2021 - 2025)

Heron Therapeutics' Convertible Debt history spans 6 years, with the latest figure at $32.7 million for Q4 2025.

  • For Q4 2025, Convertible Debt fell 78.13% year-over-year to $32.7 million; the TTM value through Dec 2025 reached $32.7 million, down 78.13%, while the annual FY2025 figure was $32.7 million, 78.13% down from the prior year.
  • Convertible Debt reached $32.7 million in Q4 2025 per HRTX's latest filing, up from $32.2 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $149.8 million in Q1 2025 to a low of $32.2 million in Q3 2025.
  • Average Convertible Debt over 5 years is $136.4 million, with a median of $149.3 million recorded in 2022.
  • The largest YoY upside for Convertible Debt was 0.14% in 2025 against a maximum downside of 78.5% in 2025.
  • A 5-year view of Convertible Debt shows it stood at $149.1 million in 2021, then increased by 0.14% to $149.3 million in 2022, then grew by 0.14% to $149.5 million in 2023, then increased by 0.14% to $149.7 million in 2024, then tumbled by 78.13% to $32.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Convertible Debt are $32.7 million (Q4 2025), $32.2 million (Q3 2025), and $149.8 million (Q1 2025).